

Oncimmune Holdings plc Results of 2021 Annual General Meeting

Following the Annual General Meeting ("AGM") of Oncimmune Holdings plc (the "Company"), which was held on 26 November 2021 at 10am at the offices of Pinsent Masons LLP, 30 Crown Place, Earl Street, London EC2A 4ES, all of the resolutions set out in the Notice of Annual General Meeting were passed by the requisite majority. Each of the resolutions put to the AGM were passed on a show of hands.

The total number of ordinary shares in respect of which proxy appointments were validly made for the AGM is 16,935,704. A summary of the proxy votes validly received prior to the AGM on each resolution is set out below.

Resolution	Votes for ⁽¹⁾		Votes against		Votes withheld ⁽²⁾
	Number	% of proxy votes received	Number	% of proxy votes received ⁽¹⁾	Number
Ordinary resolutions		'			
To receive the annual accounts and reports	16,829,154	99.37	107,025	0.63	1,032
2. To approve the Directors' Remuneration Report	15,666,670	92.5	1,269,509	7.5	1,032
3. To re-appoint Grant Thornton UK LLP as auditor	16,920,419	99.99	285	0.01	16,507
To authorise the directors to determine the auditor's remuneration.	16,935,704	100	0	0	1,507
5. To re-appoint Dr Adam M Hill	16,935,419	99.99	285	0.01	1,507



6. To re-appoint Dr Annalisa Jenkins	16,826,195	99.35	109,509	0.65	1,507
7. To authorise the Directors' authority to allot shares	16,933,980	99.99	2,199	0.01	1,032
Special Resolution					-
8. To dis-apply statutory pre-emption rights within prescribed limits.	16,756,270	98.97	175,163	1.03	5,778

- (1) Votes "for" include those votes giving the Chairman discretion.(2) A vote withheld is not a vote in law and is not counted in the calculation of the votes for or against a resolution.

The full text of all of the resolutions can be found in the Notice of Annual General Meeting which is available for viewing at the Company's website, www.oncimmune.com.

Resolutions 1 to 7 were passed as ordinary resolutions and resolution 8 was passed as special resolution.

26 November 2021